Dr Satyanarayana Reddy is well known in UK renal community for his commitment and involvement with International Multi-centred clinical research trials to improve and drive patients care. He also uses his research experience to provide the latest evidence based treatments to improve patient outcomes.
He have completed his MMedSci Research from Keele University, Stoke-on-Trent, UK. As part of his thesis he conducted: Tri-Sodium Citrate (46.7%) versus Heparin for locking of tunnelled haemodialysis Catheters — An Open Randomised clinical Trial, which is mainly to assess, if Tri-sodium Citrate (46.7%) is superior over heparin in maintaining the patency of tunnelled haemodialysis catheters and to study the antimicrobial property of Tri-sodium Citrate
Dr satyanarayana Reddy Vanga then designed and set up protocols after getting ethical approval for OPTIONS clinical trial. He is the Chief Investigator from UK for this study which is a Multicentre, International clinical trial conducted in 26 centres in 6 European countries (United Kingdom, Austria, Denmark, Germany, France and Sweden) to investigate the use of treatment options in patients presenting on dialysis in an unplanned way for which he was the Chief Investigator
Chief Investigator for an International Multi-centred trial
OPTIONS trial – This is a multi-centred International study involving 6 European countries to investigate the use of treatment options in unplanned starters on dialysis. This study also designed new educational material for unplanned starters as part of the study.
Dr Satyanarayana Reddy, Chief investigator from UK, initially conducted a Pilot study and then proceeded to design the methodology and set protocols for the study. He then got West Midlands Research Ethics Committee approval. This study is now closed for recruitment and results are being published in various international Journals.
International Research Trials as a Principal investigator while in UK:
1)Multicentre and Randomized clinical trial on management of renal anaemia in patients with chronic kidney injury with Ferinject in comparison with oral Iron.
2) Multicentre and Randomized trial to compare 2 weekly and 4 weekly Aranesp in management of renal anaemia in patients with chronic kidney disease not on dialysis.
3) H-HD trial – Multicentre trial to investigate the use of home haemodialysis.
4) CHAMPPS Study – Multicentre clinical trial in conservative management of chronic kidney disease.
5) PD One Study – Multicentre clinical trial to investigate the clinical effects of low sodium peritoneal fluid.
6)Study on supporting the emotional needs of renal patients.
7) A study of the experience of transitions to palliative care of people who are living with End Stage Renal Disease.
8) Dolomite phase 3 study -FG-4592,Roxadustat, in the Treatment of Anaemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa.
9) Bicarbonate Study – Multicentre randomized study on the use of sodium bicarbonate and its effects on renal outcomes and QOL.
10)Pyrenees Phase 3 Study 1517-CL-0613– Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis.
11)UK-Heart and Renal Protection (HARP)-3 study – Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease.